\BOOKMARK [0][-]{chapter.1}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter.2}{Introduction}{}% 2
\BOOKMARK [1][-]{section.2.1}{Emergence of antibiotic resistance}{chapter.2}% 3
\BOOKMARK [1][-]{section.2.2}{\337-lactams and resistance against this class of antibiotics}{chapter.2}% 4
\BOOKMARK [2][-]{subsection.2.2.1}{\337-lactams}{section.2.2}% 5
\BOOKMARK [2][-]{subsection.2.2.2}{Resistance of ESBL E. coli against \337-lactams}{section.2.2}% 6
\BOOKMARK [2][-]{subsection.2.2.3}{General resistance mechanisms}{section.2.2}% 7
\BOOKMARK [2][-]{subsection.2.2.4}{ESBL E. coli}{section.2.2}% 8
\BOOKMARK [1][-]{section.2.3}{Identifying mutations deciding over resistance or suscpetibility of ESBL E. coli}{chapter.2}% 9
\BOOKMARK [2][-]{subsection.2.3.1}{Principles of the morbidostat}{section.2.3}% 10
\BOOKMARK [2][-]{subsection.2.3.2}{Previous morbidostat experiments and expected outcome}{section.2.3}% 11
\BOOKMARK [2][-]{subsection.2.3.3}{Illumina and Nanopore sequning}{section.2.3}% 12
\BOOKMARK [1][-]{section.2.4}{Aim of this thesis}{chapter.2}% 13
\BOOKMARK [0][-]{chapter.3}{Materials and methods}{}% 14
\BOOKMARK [1][-]{section.3.1}{Identifying mutations in ESBL E. coli accumulated by evolving resistance against cefepim}{chapter.3}% 15
\BOOKMARK [2][-]{subsection.3.1.1}{Pipeline for identifying mutations}{section.3.1}% 16
\BOOKMARK [1][-]{section.3.2}{ESBL E. coli sampling at the University Hospital of Basel}{chapter.3}% 17
\BOOKMARK [2][-]{subsection.3.2.1}{Selection of samples suitable for our analysis}{section.3.2}% 18
\BOOKMARK [2][-]{subsection.3.2.2}{Pylogenetic analysis}{section.3.2}% 19
\BOOKMARK [1][-]{section.3.3}{Assembling and handling procedure of the morbidostat}{chapter.3}% 20
\BOOKMARK [2][-]{subsection.3.3.1}{Hardware and setup}{section.3.3}% 21
\BOOKMARK [2][-]{subsection.3.3.2}{Morbidostat modes and control}{section.3.3}% 22
\BOOKMARK [2][-]{subsection.3.3.3}{Hardware calibration}{section.3.3}% 23
\BOOKMARK [1][-]{section.3.4}{Safety aspects of morbidostat experiments}{chapter.3}% 24
\BOOKMARK [2][-]{subsection.3.4.1}{Gibson cloning}{section.3.4}% 25
\BOOKMARK [1][-]{section.3.5}{Experimental procedure for culturing with the continuous mode}{chapter.3}% 26
\BOOKMARK [2][-]{subsection.3.5.1}{MIC determination}{section.3.5}% 27
\BOOKMARK [2][-]{subsection.3.5.2}{Testing the feedback from the continuous culture mode}{section.3.5}% 28
\BOOKMARK [2][-]{subsection.3.5.3}{Culturing K12 carrying ESBL plasmids with the morbidostat}{section.3.5}% 29
\BOOKMARK [0][-]{chapter.4}{Results}{}% 30
\BOOKMARK [1][-]{section.4.1}{Analyzing ESBL E. coli isolates from patients of the University hospital Basel}{chapter.4}% 31
\BOOKMARK [2][-]{subsection.4.1.1}{Sample selection}{section.4.1}% 32
\BOOKMARK [2][-]{subsection.4.1.2}{Sequencing and assembling}{section.4.1}% 33
\BOOKMARK [2][-]{subsection.4.1.3}{SNPs}{section.4.1}% 34
\BOOKMARK [2][-]{subsection.4.1.4}{Comparing ESBL genes in the resistant samples and the susceptible samples}{section.4.1}% 35
\BOOKMARK [1][-]{section.4.2}{Morbidostat experiments}{chapter.4}% 36
\BOOKMARK [2][-]{subsection.4.2.1}{Testing the continuous experiment}{section.4.2}% 37
\BOOKMARK [2][-]{subsection.4.2.2}{Morbidostat experiment 01}{section.4.2}% 38
\BOOKMARK [2][-]{subsection.4.2.3}{Morbidostat experiment 02}{section.4.2}% 39
\BOOKMARK [0][-]{chapter.5}{Discussion}{}% 40
\BOOKMARK [1][-]{section.5.1}{Analysis of the ESBL E. coli patient isolates}{chapter.5}% 41
\BOOKMARK [2][-]{subsection.5.1.1}{SNPs}{section.5.1}% 42
\BOOKMARK [0][-]{chapter.6}{Supplementary}{}% 43
\BOOKMARK [1][-]{section.6.1}{Manual for starting experiments with morbidostat}{chapter.6}% 44
\BOOKMARK [1][-]{section.6.2}{SNPs with no annotation}{chapter.6}% 45
\BOOKMARK [0][-]{chapter.7}{Declaration}{}% 46
\BOOKMARK [0][-]{chapter.8}{References}{}% 47
\BOOKMARK [0][-]{chapter.9}{Acknowledgements}{}% 48
